Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: Biochem Pharmacol. 2006 Dec 10;73(7):1001–1012. doi: 10.1016/j.bcp.2006.11.028

Figure 3. Effect of adding neutralizing EGFR ligand antibodies on DCT-induced p44/42 MAPK phosphorylation and H508 colon cancer cell proliferation.

Figure 3

Figure 3

A–C. Effect of adding HB-EGF, EGF, and TGF-α antibodies on p44/42 MAPK phosphorylation. H508 cells were treated with DCT, EGF, HB-EGF and TGF-α for 10 minutes at 37°C, alone or with the EGFR ligand antibodies shown. p44/42 MAPK activity was determined by immunoblotting with antibodies specific for phosphorylated MAPK. The quantity of protein added was verified by immunoblotting with antibodies specific for total p42 MAPK. Results are representative of 3 separate experiments. D. Effect of adding HB-EGF antibodies and CRM197 on cell proliferation. H508 cells were incubated with DCT, alone and with antibody to HB-EGF or with CRM197 (0.1 ng/ml) for 5 days at 37°C. Cellular proliferation was determined by the sulforhodamine blue (SRB) colorimetric assay [33]. Results are mean ± SEM of 3 to 5 experiments. **P < 0.005 vs unstimulated cells.